• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Clover Health Investments Corp.

    6/17/25 4:21:44 PM ET
    $CLOV
    Medical Specialities
    Health Care
    Get the next $CLOV alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001839066
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Clover Health Investments, Corp.
    SEC File Number
    001-39252
    Address of Issuer
    30 MONTGOMERY STREET
    JERSEY CITY
    NEW JERSEY
    07302
    Phone
    (201)-432-2133
    Name of Person for Whose Account the Securities are To Be Sold
    JAMIE REYNOSO
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    2045059714.0041654157806/17/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/14/2025Restricted Stock UnitsIssuerCheckbox not checked2045003/14/2025N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    The securities to be sold were acquired upon the vesting of restricted stock units during the period of 03/14/2025 through 06/15/2025.
    Date of Notice
    06/17/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    03/13/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Jamie Reynoso

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CLOV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLOV

    DatePrice TargetRatingAnalyst
    12/17/2024$6.00Buy
    Craig Hallum
    10/7/2024$4.00Neutral
    UBS
    2/25/2022$3.00 → $2.50Market Perform
    SVB Leerink
    2/2/2022$7.00 → $3.00Underperform → Market Perform
    Cowen & Co.
    2/2/2022$6.00Buy
    Canaccord Genuity
    1/19/2022$3.00Market Perform
    SVB Leerink
    1/10/2022$9.00 → $3.50Neutral
    Citigroup
    1/7/2022$9.00 → $3.50Neutral → Underperform
    Credit Suisse
    More analyst ratings

    $CLOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Clover Health with a new price target

    Craig Hallum initiated coverage of Clover Health with a rating of Buy and set a new price target of $6.00

    12/17/24 8:33:41 AM ET
    $CLOV
    Medical Specialities
    Health Care

    UBS initiated coverage on Clover Health with a new price target

    UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00

    10/7/24 7:45:42 AM ET
    $CLOV
    Medical Specialities
    Health Care

    SVB Leerink reiterated coverage on Clover Health Investments with a new price target

    SVB Leerink reiterated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $2.50 from $3.00 previously

    2/25/22 5:03:33 AM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    SEC Filings

    View All

    Clover Health Investments Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

    8/11/25 4:31:21 PM ET
    $CLOV
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Clover Health Investments Corp.

    10-Q - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

    8/8/25 8:12:56 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Investments Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

    8/5/25 4:07:06 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel & Secretary Soares Karen covered exercise/tax liability with 7,459 shares, decreasing direct ownership by 0.51% to 1,469,487 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/18/25 5:31:54 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Director Loengard Anna U bought $68,755 worth of shares (26,500 units at $2.59) (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/14/25 4:44:26 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Chief Executive Officer Toy Andrew covered exercise/tax liability with 85,535 shares, decreasing direct ownership by 0.81% to 10,474,512 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/12/25 4:47:02 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Loengard Anna U bought $68,755 worth of shares (26,500 units at $2.59) (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/14/25 4:44:26 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Director Garipalli Vivek bought $998,997 worth of shares (446,980 units at $2.23), increasing direct ownership by 32% to 1,856,247 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/8/25 4:07:07 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Director Garipalli Vivek bought $999,596 worth of shares (531,700 units at $1.88), increasing direct ownership by 61% to 1,409,267 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/13/24 4:06:53 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Healthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA Traction

    USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Aug. 12, 2025 /PRNewswire/ -- USA News Group News Commentary – Research and development of new AI-powered tech is causing a major overhaul in the healthcare sector, with experts both optimistic and horrified at the same time. Analysts at market.us are forecasting the global AI in healthcare market to hit nearly $700 billion by 2034, growing at an explosive 38.5% CAGR along the way. With new technologies getting closer to full FDA approval, now one of the biggest hurdles for AI in healthcare is gaining the trust of clinicians and patients alike, all while proving efficacy of these new solutions. From an i

    8/12/25 11:09:00 AM ET
    $BFLY
    $CLOV
    $RDNT
    Medical Electronics
    Health Care
    Medical Specialities
    Biotechnology: Biological Products (No Diagnostic Substances)

    Clover Health Reports Second Quarter 2025 Results; Delivering Strong Sustainable Growth

    Second quarter 2025 Medicare Advantage membership of 106,323, up 32% year-over-yearSecond quarter 2025 Total revenues of $478 million, up 34% year-over-yearSecond quarter 2025 profitability metrics with GAAP Net loss of $11 million, Adjusted EBITDA of $17 million, and Adjusted Net income of $17 million Updates Full Year 2025 Guidance: Increases Average Medicare Advantage membership to 104,000 - 108,000, representing 32% growth year-over-year at the midpointMaintains Insurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpointImproves Adjusted SG&A to between $335 million and $345 million, representing Adjusted SG&A as a percentage

    8/5/25 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Primary Care Physician Use of Counterpart Assistant Technology Linked to Better Health Outcomes in Patients with Chronic Obstructive Pulmonary Disease

    New whitepaper shows that a relationship with a primary care physician ("PCP") who uses Counterpart Assistant is correlated with more frequent Chronic Obstructive Pulmonary Disease ("COPD") diagnosis, increased specialty care, and meaningful reductions in hospitalizations (15% lower) and 30-day readmissions (18% lower). WILMINGTON, Del., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover," "Clover Health" or the "Company") and a leading AI-powered physician-enablement platform, today released a new whitepaper demonstrating how Counterpart Assistant ("CA") technology supports impr

    8/4/25 4:30:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Leadership Updates

    Live Leadership Updates

    View All

    Counterpart Health Appoints Vicky Bruner as Vice President of Operations to Support Expansion and Customer Execution

    WILMINGTON, Del., July 29, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company") and a leading AI-powered physician-enablement platform, today announced the appointment of Vicky Bruner as Vice President of Operations. As Counterpart scales to meet growing demand from payors and providers nationwide, Bruner will lead several critical functions including customer implementations, provider network engagement, clinician onboarding and training, and longitudinal account support. Her work will be foundational, ensuring operational readiness and delivery consisten

    7/29/25 4:30:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Appoints Joseph Oldakowski as Vice President of Finance and Controller

    WILMINGTON, Del., July 17, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), a physician enablement company bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph (Joe) Oldakowski as Vice President of Finance and Controller. In this role, Mr. Oldakowski reports to Chief Financial Officer Peter Kuipers and will lead Clover's corporate accounting, GAAP, SEC, and statutory financial reporting and tax function. Mr. Oldakowski, who joined Clover Health in June, brings nearly two decades of experience in finance and accounting leadership across the healthcare and insurance sectors. He most recently served a

    7/17/25 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Set to Join Russell 3000® Index

    WILMINGTON, Del., June 30, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), announced that it is set to join the broad-market Russell 3000® Index, effective after the US market opens today, June 30, 2025, as part of the 2025 Russell indexes reconstitution. Annual reconstitution of the Russell indexes captures the 4,000 largest US stocks as of April 30, 2025, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, also results in automatic membership in the large-cap Russell 1000® Index or small-cap Russell 2000® Index along with the relevant growth and value style indexes. FTSE Russe

    6/30/25 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

    The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

    6/20/24 6:36:05 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Financials

    Live finance-specific insights

    View All

    Clover Health Reports Second Quarter 2025 Results; Delivering Strong Sustainable Growth

    Second quarter 2025 Medicare Advantage membership of 106,323, up 32% year-over-yearSecond quarter 2025 Total revenues of $478 million, up 34% year-over-yearSecond quarter 2025 profitability metrics with GAAP Net loss of $11 million, Adjusted EBITDA of $17 million, and Adjusted Net income of $17 million Updates Full Year 2025 Guidance: Increases Average Medicare Advantage membership to 104,000 - 108,000, representing 32% growth year-over-year at the midpointMaintains Insurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpointImproves Adjusted SG&A to between $335 million and $345 million, representing Adjusted SG&A as a percentage

    8/5/25 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health to Report Second Quarter 2025 Financial Results on August 5, 2025

    WILMINGTON, Del., July 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Tuesday, August 5, 2025. Company management will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter. Second Quarter 2025 Conference Call and Webcast Details: What: Clover Health's Second Quarter 2025 Earnings Conference CallWhen: Tuesday, August 5, 2025, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-245-3047 (for U.S. caller

    7/8/25 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance

    First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-yearFirst quarter 2025 Total revenues of $462 million, up 33% year-over-yearMedicare Advantage medical costs are in line with expectations, underscoring the strength of Clover's technology-first care management modelMeaningful improvement across first quarter 2025 profitability metrics: GAAP Net loss of $1 million, as compared to a GAAP Net loss of $19 million a year agoAdjusted EBITDA of $26 million, up 279% year-over-yearAdjusted Net income of $25 million, up 322% year-over-year Improved Full Year 2025 Guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year

    5/6/25 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

    SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

    11/12/24 2:31:31 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

    SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

    11/4/24 11:25:56 AM ET
    $CLOV
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Clover Health Investments Corp. (Amendment)

    SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

    7/7/23 4:35:52 PM ET
    $CLOV
    Medical Specialities
    Health Care